Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | PNMT | P11086 | 2/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16649685 | 1.00 | TAAR1 (0.47) | TAAR1PNMTGBA1HRH1AOC3 | |
| SCHEMBL28104541 | 0.89 | TAAR1 (0.42) | TAAR1PNMTGBA1HRH1AOC3 | |
| SCHEMBL25269085 | 0.86 | PNMT (0.47) | PNMTGBA1AOC3OPRM1OPRD1 | |
| SCHEMBL382070 | 0.86 | PNMT (0.47) | PNMTGBA1AOC3OPRM1OPRD1 | |
| SCHEMBL19053623 | 0.86 | PNMT (0.47) | TAAR1PNMTGBA1AOC3OPRM1 | |
| SCHEMBL9903831 | 0.86 | PNMT (0.47) | TAAR1PNMTGBA1AOC3OPRM1 | |
| SCHEMBL16692504 | 0.85 | OPRM1 (0.49) | PNMTGBA1AOC3OPRM1OPRD1 | |
| SCHEMBL5652929 | 0.85 | OPRM1 (0.49) | PNMTGBA1AOC3OPRM1OPRD1 | |
| SCHEMBL5947869 | 0.84 | HRH1 (0.59) | TAAR1PNMTHRH1AOC3IDO1 | |
| SCHEMBL3489363 | 0.82 | GBA1 (0.48) | PNMTGBA1AOC3OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073871-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-04-11 | — | — | WO | disclosed |
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | TAAR1 3427/4885PNMT 979/4885GBA1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.